MorphoSys Opts for Second Pre-Development Program within Strategic Antibody Alliance
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Opts for Second Pre-Development Program within Strategic Antibody
Alliance
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Further Expansion of the Company's Proprietary Development Activities
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that
within its collaboration with Novartis it has nominated the second therapeutic
antibody program for joint pre-development. The pre-development agreement
provides MorphoSys with the option to enter a formal co-development for the
respective program with Novartis. Until the program reaches formal co-
development status, Novartis carries all "project-related" costs. MorphoSys's
share of the funded research will add to revenues in its Proprietary Development
segment.
The first pre-development candidate with Novartis was announced in September
2008, giving MorphoSys the opportunity to benefit from working with a very
experienced pharmaceutical partner and strengthening its own drug development
capabilities.
"The options on pre-development with Novartis are an important contribution to
our proprietary development activities. Including this latest addition to our
pipeline, we currently pursue nine proprietary programs and partnered
candidates", commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys
AG. "For the second time within this co-operation, we have chosen the
opportunity to jointly develop an antibody candidate against a very promising
target involved in inflammatory conditions, one of our core development areas.
Over the past years, MorphoSys has built a strong proprietary development
organization and progress in this segment is increasingly becoming visible."
Within its strategic collaboration with Novartis signed in 2007, MorphoSys has
the potential for several co-development options which enable MorphoSys to
participate in the development of a selection of projects through cost and
profit sharing with financial participation reflecting its level of investment
in the respective programs.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visit http://www.morphosys.com/
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®) and RapMAT(®) are
registered trademarks of MorphoSys.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
[HUG#1452827]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,CDAX,Prime All Share,TECH All Share,HDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Press Release:
http://hugin.info/130295/R/1452827/393530.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 19.10.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 45871
Anzahl Zeichen: 0
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Opts for Second Pre-Development Program within Strategic Antibody Alliance"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
